Laboratorio Clínico, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
PLoS One. 2020 Jan 9;15(1):e0227776. doi: 10.1371/journal.pone.0227776. eCollection 2020.
Coinfections of HIV patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) are mayor public health problems, contributing to the emerging burden of HIV-associated hepatic mortality. Coinfection rates vary geographically, depending on various factors such as predominant transmission modes, HBV vaccination rates, and prevalence of HBV and HCV in the general population. In South America, the epidemiology of coinfections is uncertain, since systematic studies are scarce. Our study aimed to analyze rates of HBV and HCV infection in people living with HIV attending centers of the public and private health system in Chile.
We performed a cross-sectional study including a public university hospital and a private health center in Santiago, Metropolitan Region in Chile. Serum samples were used to determine serological markers of hepatitis B (HBsAg, anti-HBs, anti-HBc total, HBeAg, anti-HBe) and anti-HCV. Demographic, clinical and laboratory data were obtained from medical records.
399 patients were included (353 from public, 46 from private health center). Most (92.8%) were male, with a median age of 38.3 years; 99.4% acquired HIV through sexual contact (75.0% MSM); 25.7% had AIDS and 90.4% were on ART. In 78.9%, viral loads were <40 cps/mL; the median CD4 cell count was 468 cells/mm3. According to their serological status, 37.6% of patients were HBV naïve (susceptible), 6.5% were vaccinated, 43.6% had resolved HBV infection, and 5.8% were chronically infected. The rate of vaccination was 4.5% in the public and 21.7% in the private system. HCV coinfection was found in 1.0% of all patients.
HBV coinfection rate was within the range of other South American countries, but lower than in non-industrialized regions in Asia and Africa. A low percentage of patients were HBV vaccinated, especially within the public system. HCV coinfection rate was very low, most probably due to the rareness of injecting drug use.
艾滋病毒(HIV)患者合并乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染是重大公共卫生问题,导致与 HIV 相关的肝死亡率不断增加。合并感染率因地理位置而异,这取决于多种因素,如主要传播模式、HBV 疫苗接种率以及HBV 和 HCV 在普通人群中的流行率。在南美洲,由于系统研究较少,合并感染的流行病学情况尚不确定。本研究旨在分析在智利公共和私营卫生系统的 HIV 感染者中 HBV 和 HCV 感染的发生率。
我们进行了一项横断面研究,包括智利圣地亚哥的一所公立大学医院和一家私人保健中心。使用血清样本确定乙型肝炎的血清学标志物(HBsAg、抗-HBs、抗-HBc 总抗体、HBeAg、抗-HBe)和抗-HCV。从病历中获取人口统计学、临床和实验室数据。
共纳入 399 例患者(353 例来自公立,46 例来自私立保健中心)。大多数(92.8%)为男性,中位年龄 38.3 岁;99.4%经性接触感染 HIV(75.0%为男男性接触者);25.7%患有艾滋病,90.4%正在接受抗逆转录病毒治疗。在 78.9%的患者中,病毒载量<40cps/ml;中位 CD4 细胞计数为 468 个细胞/mm3。根据其血清学状态,37.6%的患者为 HBV 初治者(易感),6.5%已接种疫苗,43.6%已清除 HBV 感染,5.8%为慢性感染。公立系统中接种疫苗的比例为 4.5%,私立系统为 21.7%。所有患者中 HCV 合并感染率为 1.0%。
HBV 合并感染率在其他南美国家范围内,但低于亚洲和非洲非工业化地区。HBV 疫苗接种率较低,尤其是在公立系统中。HCV 合并感染率非常低,这可能是由于注射吸毒的罕见。